OvaScience Inc (OVAS.O), a developer of infertility treatments, said it plans to suspend enrollment in a U.S. study testing its lead product after regulators sought an application for the product’s approval, sending the company’s stock down 44 percent.
FDA Demands OvaScience Apply for Product Approval; Shares Slump
